Summary
Global Markets Direct’s, ‘Burkitt Lymphoma - Pipeline Review, H1 2016’, provides an overview of the Burkitt Lymphoma pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Burkitt Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Burkitt Lymphoma and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Burkitt Lymphoma
- The report reviews pipeline therapeutics for Burkitt Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Burkitt Lymphoma therapeutics and enlists all their major and minor projects
- The report assesses Burkitt Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Burkitt Lymphoma
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Burkitt Lymphoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Burkitt Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
AbbVie Inc.
Arvinas, Inc.
AstraZeneca Plc
Bluebird bio, Inc.
Constellation Pharmaceuticals, Inc.
Immunomedics, Inc.
Karyopharm Therapeutics, Inc.
Millennium Pharmaceuticals, Inc.
Seattle Genetics, Inc.
Takeda Pharmaceutical Company Limited
Theravectys SA
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Burkitt Lymphoma Overview 8
Therapeutics Development 9
Pipeline Products for Burkitt Lymphoma - Overview 9
Pipeline Products for Burkitt Lymphoma - Comparative Analysis 10
Burkitt Lymphoma - Therapeutics under Development by Companies 11
Burkitt Lymphoma - Therapeutics under Investigation by Universities/Institutes 12
Burkitt Lymphoma - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Burkitt Lymphoma - Products under Development by Companies 15
Burkitt Lymphoma - Products under Investigation by Universities/Institutes 16
Burkitt Lymphoma - Companies Involved in Therapeutics Development 17
AbbVie Inc. 17
Arvinas, Inc. 18
AstraZeneca Plc 19
Bluebird bio, Inc. 20
Constellation Pharmaceuticals, Inc. 21
Immunomedics, Inc. 22
Karyopharm Therapeutics, Inc. 23
Millennium Pharmaceuticals, Inc. 24
Seattle Genetics, Inc. 25
Takeda Pharmaceutical Company Limited 26
Theravectys SA 27
Burkitt Lymphoma - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Target 29
Assessment by Mechanism of Action 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
19-3s - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
20-3s - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
alisertib - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
ARV-825 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
AZD-6738 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
bb-2121 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
denintuzumab mafodotin - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
E1-3s - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Epstein-Barr virus vaccine - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
ibrutinib - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
ixazomib citrate - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Monoclonal Antibody Conjugate to Target CD20 for Leukemia and Burkitt Lymphoma - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
selinexor - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
SH-7129 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
SH-7133 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
SH-7139 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Small Molecules to Inhibit BET for Cancer - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Burkitt Lymphoma - Recent Pipeline Updates 76
Burkitt Lymphoma - Dormant Projects 113
Appendix 114
Methodology 114
Coverage 114
Secondary Research 114
Primary Research 114
Expert Panel Validation 114
Contact Us 114
Disclaimer 115
List of Tables
Number of Products under Development for Burkitt Lymphoma, H1 2016 9
Number of Products under Development for Burkitt Lymphoma - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Number of Products under Investigation by Universities/Institutes, H1 2016 12
Comparative Analysis by Clinical Stage Development, H1 2016 13
Comparative Analysis by Early Stage Development, H1 2016 14
Products under Development by Companies, H1 2016 15
Products under Investigation by Universities/Institutes, H1 2016 16
Burkitt Lymphoma - Pipeline by AbbVie Inc., H1 2016 17
Burkitt Lymphoma - Pipeline by Arvinas, Inc., H1 2016 18
Burkitt Lymphoma - Pipeline by AstraZeneca Plc, H1 2016 19
Burkitt Lymphoma - Pipeline by Bluebird bio, Inc., H1 2016 20
Burkitt Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H1 2016 21
Burkitt Lymphoma - Pipeline by Immunomedics, Inc., H1 2016 22
Burkitt Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 23
Burkitt Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 24
Burkitt Lymphoma - Pipeline by Seattle Genetics, Inc., H1 2016 25
Burkitt Lymphoma - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 26
Burkitt Lymphoma - Pipeline by Theravectys SA, H1 2016 27
Assessment by Monotherapy Products, H1 2016 28
Number of Products by Stage and Target, H1 2016 30
Number of Products by Stage and Mechanism of Action, H1 2016 32
Number of Products by Stage and Route of Administration, H1 2016 34
Number of Products by Stage and Molecule Type, H1 2016 36
Burkitt Lymphoma Therapeutics - Recent Pipeline Updates, H1 2016 76
Burkitt Lymphoma - Dormant Projects, H1 2016 113
List of Figures
Number of Products under Development for Burkitt Lymphoma, H1 2016 9
Number of Products under Development for Burkitt Lymphoma - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 13
Comparative Analysis by Early Stage Products, H1 2016 14
Assessment by Monotherapy Products, H1 2016 28
Number of Products by Top 10 Targets, H1 2016 29
Number of Products by Stage and Top 10 Targets, H1 2016 29
Number of Products by Top 10 Mechanism of Actions, H1 2016 31
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 31
Number of Products by Routes of Administration, H1 2016 33
Number of Products by Stage and Routes of Administration, H1 2016 33
Number of Products by Molecule Types, H1 2016 35
Number of Products by Stage and Molecule Types, H1 2016 35
